SEQUENTIAL TOPOTECAN & ETOPOSIDE FOR PATIENTS WITH MYELOID LEUKEMIA

本研究的目的是确定 序贯拓扑替康72小时输注， 复发性或难治性急性髓系白血病患者每日服用依托泊苷 白血病 目的是确定最大耐受剂量 并描述毒性。 已入组8例患者。 7例患者的 他们的疾病和一名患者被取消了在医生的研究 自行决定 患者目前正在接受剂量水平2的治疗。 的 试验将继续增加患者。

The purpose of this study is to determine the toxicity and efficacy of sequential topotecan administered as a 72 hour infusion followed by daily etoposide in patients with relapsed or refractory acute myeloid leukemia. The objectives are to determine the maximum tolerated dose and to describe the toxicity. Eight patients have been enrolled. Seven patients had no change in their disease and one patient was taken off study at the physician's discretion. Patients are currently being treated at dose level 2. The trial will continue to accrue patients.